Kerendia®▼(finerenone) is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.
For adult patients with Chronic Kidney Disease and Type 2 Diabetes
Despite standard of care, patients with CKD in T2D are at risk of CV events, ESKD, and dialysis
CKD is ~2x more prevalent in patients with T2D vs those without
Life expectancies of patients with both T2D and CKD are on average 16 years shorter than those without
Patients with both T2D and CKD are ~3x more likely to die of CV-related causes than patients with T2D alone
The Silent Epidemic:
Early CKD Detection for Kidney and Diabetes Health
This infographic explores the current state of kidney disease in the UK and highlights how Kerendia can support your eligible CKD associated T2D patients.
Abbreviations:
CKD, chronic kidney disease. CV, cardiovascular. ESKD, end-stage kidney disease. T2D, type 2 diabetes.
PP-KER-GB-0825 | July 2025